Clinical Trials Directory

Trials / Completed

CompletedNCT01982968

Treatment of IPF With Laparoscopic Anti-Reflux Surgery

Weighing Risks and Benefits of Laparoscopic Anti-Reflux Surgery in Patients With Idiopathic Pulmonary Fibrosis

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
58 (actual)
Sponsor
University of California, San Francisco · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

This study will test the hypothesis that treatment with laparoscopic anti-reflux surgery in subjects with idiopathic pulmonary fibrosis (IPF) and abnormal gastroesophageal reflux (GER) will slow the decline of forced vital capacity (FVC) over 48 weeks.

Detailed description

This protocol proposes to test the following hypothesis: Treatment with laparoscopic anti-reflux surgery in subjects with idiopathic pulmonary fibrosis (IPF) and abnormal gastroesophageal (GER) reflux will slow the decline of forced vital capacity (FVC) over 48 weeks. This study will randomize approximately 58 subjects with IPF and abnormal acid reflux on 24-hour impedance / pH monitoring to laparoscopic anti-reflux surgery or standard care (randomization ratio 1:1). Subjects will be followed for 48 weeks or until the time of lung transplantation or death. We aim to achieve the following: determine the impact of laparoscopic anti-reflux surgery on change in FVC over 48 weeks in patients with IPF and abnormal GER; correlate the reduction in acid and non-acid reflux events with the change in FVC over 48 weeks in patients with IPF and abnormal GER; determine the safety of laparoscopic anti-reflux surgery in patients with IPF and abnormal GER; explore the impact of laparoscopic anti-reflux surgery on key secondary endpoints over 48 weeks in patients with IPF and abnormal GER; identify molecular markers of IPF disease activity and gastroesophageal reflux in biological samples from patients with IPF and abnormal GER.

Conditions

Interventions

TypeNameDescription
PROCEDURESurgeryFull fundoplication surgery for the treatment of abnormal GER

Timeline

Start date
2013-12-01
Primary completion
2017-11-01
Completion
2017-11-01
First posted
2013-11-13
Last updated
2021-10-25
Results posted
2021-10-25

Locations

5 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01982968. Inclusion in this directory is not an endorsement.